{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:35:23Z","timestamp":1774352123813,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1053\/j.ajkd.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:20:27Z","timestamp":1755498027000},"page":"710-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report"],"prefix":"10.1053","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-9988","authenticated-orcid":false,"given":"Api","family":"Chewcharat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raad B.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2025.06.014_bib1","article-title":"Atypical hemolytic uremic syndrome: cancer-induced or chemotherapy-induced?","volume":"13","author":"Sethi","year":"2021","journal-title":"Cureus"},{"issue":"11","key":"10.1053\/j.ajkd.2025.06.014_bib2","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.014_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","article-title":"Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report","volume":"11","author":"Facchini","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1053\/j.ajkd.2025.06.014_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.014_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","article-title":"Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution","volume":"84","author":"M\u00fcller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1053\/j.ajkd.2025.06.014_bib6","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.014_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.06.014_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"10.1053\/j.ajkd.2025.06.014_bib9","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.014_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.014_bib11","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.014_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"issue":"16","key":"10.1053\/j.ajkd.2025.06.014_bib13","first-page":"30178","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","volume":"S1533-0028","author":"Turner","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.014_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.014_bib15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ekir.2021.03.001","article-title":"Treatment of gemcitabine-induced thrombotic microangiopathy followed by gemcitabine rechallenge with eculizumab","volume":"6","author":"Efe","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"11S","key":"10.1053\/j.ajkd.2025.06.014_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1681\/ASN.20233411S1782d","article-title":"Rechallenging gemcitabine with eculizumab in a patient with gemcitabine-induced thrombotic microangiopathy: SA-PO216","volume":"34","author":"Sharma","year":"2023","journal-title":"J Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:20:02Z","timestamp":1760998802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625009771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0272638625009771"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.014","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}